Myomo, Inc. reported financial results for the second quarter ended June 30, 2026, announcing revenue of $11.7 million, a 21% increase year-over-year. The company raised its full-year revenue guidance to $45-47 million and expects third-quarter revenue between $11.5 million and $12.0 million. Second-quarter gross margin expanded to 72.1%, up from 62.7%, while operating expenses remained roughly flat, resulting in an adjusted EBITDA loss of $0.8 million compared to a $4.0 million loss in the prior year period. Net loss was $4.0 million, or $0.09 per share. The company operates in the wearable medical robotics industry, developing devices like the MyoPro to restore arm and hand function for patients with neurological disorders.

At its Annual Meeting of Stockholders on June 25, 2026, Myomo, Inc. stockholders approved an amendment to the company's Eighth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 100,000,000. Additionally, stockholders approved Amendment No. 3 to the Myomo 2018 Stock Option and Incentive Plan, increasing the number of shares available under the plan by 1,833,000 shares. Other approved items included the election of Paul R. Gudonis and Thomas F. Kirk as Class III directors and the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2026. Myomo, Inc. operates in the healthcare technology industry, providing robotic assistive devices for individuals with neuromuscular disorders.

At its June 25, 2026, Annual Meeting of Stockholders, Myomo, Inc. approved an amendment to its 2018 Stock Option and Incentive Plan to increase available shares by 1,833,000. Additionally, stockholders approved a charter amendment to increase the total authorized common stock to 100,000,000 shares, which became effective upon filing with the Delaware Secretary of State. The meeting also resulted in the election of Paul R. Gudonis and Thomas F. Kirk as Class III directors and the ratification of CBIZ CPAs P.C. as the independent auditor. Myomo, Inc. is a medical technology company that develops wearable robotic devices.